Arcus Biosciences, Inc.
RCUSNYSEHealthcare● Active
$23.78
+$0.59(+2.54%)
Market Cap$2.4B
P/E Ratio—
52W High$28.72
52W Low$7.91
Arcus Biosciences, Inc. (RCUS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RCUS · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
-$1.02
Est. -$0.92 · -10.9%
Revenue
$0.02B
Est. $0.03B · -42.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
RCUS reports quarterly as a NYSE-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | -$0.89 | — | — | — | $0.02B | — |
| ▼ Q2 FY2026 | May 5, 2026 | -$0.92 | -$1.02 | -10.9% | $0.02B | $0.03B | -42.3% |
| ▲ Q1 FY2026 | Feb 25, 2026 | -$1.11 | -$0.89 | +19.8% | $0.03B | $0.04B | -7.6% |
| ▲ Q4 FY2025 | Oct 28, 2025 | -$1.33 | -$1.27 | +4.5% | $0.03B | $0.02B | +4.3% |
| ▲ Q3 FY2025 | Aug 6, 2025 | -$1.14 | -$0.08 | +93.4% | $0.16B | $0.03B | +392.6% |
| ▼ Q2 FY2025 | May 6, 2025 | -$1.02 | -$1.14 | -11.8% | $0.03B | $0.04B | -25.1% |
| ▲ Q1 FY2025 | Feb 25, 2025 | -$1.17 | -$1.03 | +12.0% | $0.03B | $0.03B | -11.5% |
| ▲ Q4 FY2024 | Nov 6, 2024 | -$1.07 | -$1.00 | +6.5% | $0.05B | $0.03B | +49.7% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
-$0.89
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Miss
EPS Actual
-$1.02
EPS Est.
-$0.92
EPS Surpr.
-10.9%
Revenue
$0.02B
Q1 FY2026
Feb 25, 2026Beat
EPS Actual
-$0.89
EPS Est.
-$1.11
EPS Surpr.
+19.8%
Revenue
$0.03B
Q4 FY2025
Oct 28, 2025Beat
EPS Actual
-$1.27
EPS Est.
-$1.33
EPS Surpr.
+4.5%
Revenue
$0.03B
Q3 FY2025
Aug 6, 2025Beat
EPS Actual
-$0.08
EPS Est.
-$1.14
EPS Surpr.
+93.4%
Revenue
$0.16B
Q2 FY2025
May 6, 2025Miss
EPS Actual
-$1.14
EPS Est.
-$1.02
EPS Surpr.
-11.8%
Revenue
$0.03B
Q1 FY2025
Feb 25, 2025Beat
EPS Actual
-$1.03
EPS Est.
-$1.17
EPS Surpr.
+12.0%
Revenue
$0.03B
Q4 FY2024
Nov 6, 2024Beat
EPS Actual
-$1.00
EPS Est.
-$1.07
EPS Surpr.
+6.5%
Revenue
$0.05B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2029 | $-0.32 | $-0.26 | $-0.20 | 2 |
| Q3 FY2029 | $-0.44 | $-0.36 | $-0.27 | 1 |
| Q2 FY2029 | $-0.54 | $-0.43 | $-0.34 | 1 |
| Q1 FY2029 | $-0.63 | $-0.51 | $-0.39 | 2 |
| Q4 FY2028 | $-0.69 | $-0.56 | $-0.43 | 3 |
| Q3 FY2028 | $-0.90 | $-0.72 | $-0.55 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2029 | $0.2B | $0.2B | $0.2B | 3 |
| Q3 FY2029 | $0.1B | $0.2B | $0.2B | 3 |
| Q2 FY2029 | $0.1B | $0.1B | $0.2B | 3 |
| Q1 FY2029 | $0.1B | $0.1B | $0.1B | 5 |
| Q4 FY2028 | $0.1B | $0.1B | $0.1B | 4 |
| Q3 FY2028 | $0.0B | $0.1B | $0.1B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 5, 2026 | -10.9% | $26.05 | $26.06 | +0.04% |
| ▲ Q1 FY2026 | Feb 25, 2026 | +19.8% | $20.19 | $20.27 | +0.40% |
| ▲ Q4 FY2025 | Oct 28, 2025 | +4.5% | $18.60 | $19.88 | +6.88% |
| ▲ Q3 FY2025 | Aug 6, 2025 | +93.4% | $9.55 | $9.49 | -0.63% |
| ▼ Q2 FY2025 | May 6, 2025 | -11.8% | $8.94 | $8.12 | -9.17% |
| ▲ Q1 FY2025 | Feb 25, 2025 | +12.0% | $10.16 | $10.24 | +0.79% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +6.5% | $15.29 | $15.73 | +2.88% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +0.0% | $14.00 | $13.69 | -2.21% |
Q2 FY2026+0.04%
Report Date
May 5, 2026
EPS Beat/Miss
-10.9%
Price Before
$26.05
Price After
$26.06
Q1 FY2026+0.40%
Report Date
Feb 25, 2026
EPS Beat/Miss
+19.8%
Price Before
$20.19
Price After
$20.27
Q4 FY2025+6.88%
Report Date
Oct 28, 2025
EPS Beat/Miss
+4.5%
Price Before
$18.60
Price After
$19.88
Q3 FY2025-0.63%
Report Date
Aug 6, 2025
EPS Beat/Miss
+93.4%
Price Before
$9.55
Price After
$9.49
Q2 FY2025-9.17%
Report Date
May 6, 2025
EPS Beat/Miss
-11.8%
Price Before
$8.94
Price After
$8.12
Q1 FY2025+0.79%
Report Date
Feb 25, 2025
EPS Beat/Miss
+12.0%
Price Before
$10.16
Price After
$10.24
Q4 FY2024+2.88%
Report Date
Nov 6, 2024
EPS Beat/Miss
+6.5%
Price Before
$15.29
Price After
$15.73
Q3 FY2024-2.21%
Report Date
Aug 8, 2024
EPS Beat/Miss
+0.0%
Price Before
$14.00
Price After
$13.69
Avg Beat Reaction+1.35%
Avg Miss Reaction-4.57%
Beat Rate6 / 8 quarters
Largest Move-9.17% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RCUS ends December
Arcus Biosciences, Inc. (RCUS) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $-1.02 — missing the analyst consensus of $-0.92 by -10.9%. The next RCUS earnings date is expected around September 1, 2026.
Each quarter, investors track RCUS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RCUS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RCUS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RCUS earnings · 5 questionsArcus Biosciences, Inc.'s next earnings report is expected around September 1, 2026. RCUS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RCUS historically reports after market close (AMC).
RCUS earnings datewhen is RCUS earningsRCUS next earnings datewhen does RCUS report earningsRCUS earnings calendar
▸ Source: FMP · Arcus Biosciences, Inc. SEC filings · US GAAP · Arcus Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026